Compositions and methods for treating cancer
Compositions comprising SEQ ID NO: 1 and methods of treating a MUC16-expressing tumor cell are described.
1. A fusion peptide comprising:
a cell delivery domain or a cell transduction domain, and
a polypeptide comprising the amino acid sequence XLIXGVLVTTRRRKK (SEQ ID NO:1), wherein the polypeptide is less than 50 amino acids in length.
2. The fusion peptide of claim 1 , wherein the polypeptide comprises the amino acid sequence CLICGVLVTTRRRKK (SEQ ID NO:2).
3. The fusion peptide of claim 1 , wherein the polypeptide comprises all L-amino acids.
4. The fusion peptide of claim 1 , wherein the polypeptide comprises all D-amino acids.
5. The fusion peptide of claim 1 , wherein the polypeptide comprises a mixture of L- and D-amino acids.
6. The fusion peptide of claim 1 , wherein the cell transduction domain is an HIV tat cell transduction domain.
7. The fusion peptide of claim 1 , wherein the cell delivery domain is a poly-D-R, poly D-P, or poly D-K.
8. A composition comprising the fusion peptide of claim 1 and a pharmaceutically acceptable carrier, buffer, or diluent.
9. A method of inhibiting the growth of a MUC16 positive tumor cell in a subject, comprising administering to the subject a composition comprising:
(a) a fusion peptide comprising:
(i) a cell delivery domain or a cell transduction domain, and
(ii) a polypeptide comprising the amino acid sequence XLIXGVLVTTRRRKK (SEQ ID NO: 1), wherein the polypeptide is less than 50 amino acids in length; and
(b) a pharmaceutically acceptable carrier, buffer, or diluent.
10. The method of claim 9 , wherein the tumor is an ovarian tumor, a pancreatic tumor, an esophageal tumor, a gastric tumor, or a colon tumor.
11. The method of claim 9 , wherein the administering is local, regional, systemic, or continual administration.
12. The method of claim 9 , further comprising administering to the subject a second anti-cancer therapy.
13. The method of claim 12 , wherein the second anti-cancer therapy is surgery, chemotherapy, radiotherapy, hormonal therapy, toxin therapy, immunotherapy, or cryotherapy.
14. The method of claim 12 , wherein the second anti-cancer therapy is administered prior to, after, or concurrently with the fusion peptide.
15. The method of claim 9 , wherein the polypeptide comprises the amino acid sequence CLICGVLVTTRRRKK (SEQ ID NO:2).
16. The method of claim 9 , wherein the polypeptide comprises all L-amino acids.
17. The method of claim 9 , wherein the polypeptide comprises all D-amino acids.
18. The method of claim 9 , wherein the polypeptide comprises a mixture of L- and D-amino acids.
19. The method of claim 9 , wherein the cell transduction domain is an HIV tat cell transduction domain.
20. The method of claim 9 , wherein the cell delivery domain is poly-D-R, poly D-P, or poly D-K.